Anika Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Anika Therapeutics

02/11/2023 21:45

* Anika Therapeutics Inc  ANIK.OQ  reported a quarterly
adjusted
loss of 45 cents​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of -15 cents.  The mean expectation of three analysts for
the quarter was for a loss of 37 cents per share. Wall Street
expected results to range from -43 cents to -33 cents per share.
    * Revenue rose 3% to $41.47 million from a year ago;
analysts
expected $38.27 million. 
    * Anika Therapeutics Inc's reported EPS for the quarter was
a loss
of 45 cents​.
    * The company reported a quarterly loss of $6.58 million.
    * Anika Therapeutics Inc shares had risen by 5.6% this
quarter and
lost 33.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 40.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Anika
Therapeutics Inc is $24.00 
This summary was machine generated from LSEG data November 2 at
09:45 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.37          -0.45          Missed
 Jun. 30 2023      -0.27          -0.19          Beat
 Mar. 31 2023      -0.30          -0.47          Missed
 Dec. 31 2022      -0.24          -0.34          Missed